Combining Biologics in a Young Patient with Atopic Dermatitis

Program Overview

Tune in as a multidisciplinary panel discusses a clinician’s question about the appropriateness of combining 2 biologics in a very young child with several atopic diseases.

Credit Expired

Target Audience

The target audience for this activity is US-based dermatologists, allergists, and immunologists, as well as NPs and PAs that diagnose and manage atopic dermatitis (AD). Primary care clinicians will also be included as a secondary audience.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management
Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, assessment of treatment response, and strategies to optimize short-term control and long-term management of the disease
Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

Activity Faculty

Peter A. Lio, MD (Chair)

Assistant Professor, Clinical Dermatology and Pediatrics
Northwestern University
Feinberg School of Medicine
Ann & Robert H. Lurie Children’s Hospital
Chicago, IL

Mark Boguniewicz, MD

Professor, Division of Allergy-Immunology
Department of Pediatrics
National Jewish Health and University of Colorado School of Medicine
Denver, CO

Eric L. Simpson, MD, MCR

Professor, Dermatology
Director, Clinical Research
Department of Dermatology
Oregon Health & Science University
Portland, OR

Featured RMEI CE Activities – Earn CE Credit(s)

Combining Biologics in a Young Patient with Atopic Dermatitis

Program Overview

Target Audience

Educational Objectives

Activity Faculty

Peter A. Lio, MD (Chair)

Mark Boguniewicz, MD

Eric L. Simpson, MD, MCR

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

Refining Management of CMV After Transplant: Exploiting Recent Advances to Alleviate Patient Burden

Overcoming Obstacles to Optimal Multiple Sclerosis (MS) Care in Minority Patient Populations

Subscribe